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Abstract 32 
Background: In animal models of cardiac arrest, the benefit afforded by hypothermia is 33 
closely linked to the rapidity in body temperature decrease after resuscitation. Since total 34 
liquid ventilation (TLV) with temperature controlled perfluorocarbons induces a very rapid 35 
and generalized cooling, we aimed to determine whether this could limit the post-cardiac 36 
arrest syndrome in a rabbit model. We especially focused on neurological, cardiac, 37 
pulmonary, liver and kidney dysfunctions.  Methods and Results: Anesthetized rabbits were 38 
submitted to either 5 or 10-min of untreated ventricular fibrillation. After cardiopulmonary 39 
resuscitation and resumption of a spontaneous circulation, the animals underwent either 40 
normothermic life support (control) or therapeutic hypothermia induced by TLV. The latter 41 
procedure decreased esophagal and tympanic temperatures to 32-33°C within only 10-min. 42 
After rewarming, the animals submitted to TLV exhibited an attenuated neurological 43 
dysfunction and decreased mortality 7 days later as compared to control.  The 44 
neuroprotective effect of TLV was confirmed by a significant reduction in brain histological 45 
damages. We also observed limitation of myocardial necrosis, along with a decrease in 46 
troponin I release and a reduced myocardial caspase 3 activity with TLV. The beneficial 47 
effects of TLV were directly related to the rapidity at inducing hypothermia since neither 48 
conventional cooling (cold saline infusion + external cooling) nor normothermic TLV elicited 49 
a similar protection.   Conclusions: Ultra-fast cooling instituted by TLV exerts potent 50 
neurological and cardiac protections in an experimental model of cardiac arrest in rabbits. 51 
This could be a relevant approach to afford a global and protective hypothermia against the 52 
post-cardiac arrest syndrome. 53 
 54 
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Introduction 56 
Institution of mild “therapeutic” hypothermia (32-34°C) during 24 to 36 hours after 57 
resuscitation is known to improve survival and neurological recovery in comatose survivors 58 
of cardiac arrest.1, 2 However, experimental studies in dogs,3, 4 pigs5, 6 and rodents7, 8 59 
demonstrated that the neuroprotection afforded by hypothermia was related to the rapidity 60 
in body temperature decrease after resuscitation. When achieved rapidly, hypothermia 61 
could also be beneficial for other organs since it can be, for example, also potently 62 
cardioprotective during myocardial ischemia.9-12 Accordingly, many strategies were 63 
proposed to afford such a rapid hypothermia, including intravenous infusion of cold fluid,13 64 
endovascular 14 or intranasal cooling.15, 16 65 
Another strategy that can experimentally afford a very rapid and generalized cooling 66 
is liquid ventilation of the lungs with temperature-controlled perfluorocarbons.11, 17-22 These 67 
liquids can use the lungs as heat exchangers while maintaining normal gas exchanges. 18-20 68 
In addition, this ventilation procedure also protects the lung integrity.20 Using a prototype of 69 
total liquid ventilator that alternatively instillates and removes a tidal volume of 70 
perfluorocarbon from the lung, we were able to decrease the left atrial temperature to 32°C 71 
within only 5 min in anesthetized rabbits.11, 17, 18 This was associated with a very potent 72 
protection against myocardial infarction and subsequent contractile dysfunction in animal 73 
models of coronary artery occlusion.11, 17, 18 In a swine model of ventricular fibrillation, liquid 74 
ventilation also induced a rapid convective cooling that further improves the chances for 75 
subsequent resumption of spontaneous circulation. 21, 22 However, the effect of hypothermic 76 
total liquid ventilation (TLV) has never been investigated to our knowledge in animal models 77 
of post-cardiac arrest dysfunction when instituted after resumption of spontaneous 78 
circulation. 79 
Accordingly, the main purpose of the present study was to investigate the long term 80 
effect of ultrafast cooling induced by TLV in a rabbit model of post-cardiac arrest 81 
dysfunction following ventricular fibrillation and resuscitation. In order to determine whether 82 
hypothermic TLV properly protects through very fast cooling, we investigated two additional 83 
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groups submitted to a conventional hypothermia (cold saline infusion + external cooling) or 84 
to normothermic TLV. The primary outcome was the survival during 7 days of follow-up. 85 
The secondary outcomes were clinical, biochemical, hemodynamic and histological 86 
parameters describing neurological, cardiac, pulmonary, liver and kidney potential 87 
dysfunctions. We also aimed to investigate whether ultra-fast cooling can protect the heart 88 
through an early inhibition of cardiac cell death. The latter point was also critical to further 89 
support the relevance of very fast cooling to limit the subsequent dysfunction following 90 
cardiac arrest.  91 
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Methods 92 
The animal instrumentation and ensuing experiments were conducted in accordance 93 
with French official regulations (agreement A94-046-13) after approval by the local ethical 94 
committee. The investigation conformed to the Guide for the Care and Use of Laboratory 95 
Animals published by the US National Institutes of Health.   96 
Animal preparation 97 
New Zealand rabbits (3.0-3.5 kg) were anesthetized using zolazepam, tiletamine and 98 
pentobarbital (all 20-30 mg/kg i.v.). They were intubated and mechanically ventilated. After 99 
administration of pancuronium bromide (200 µg/kg i.v.), two electrodes were implanted 100 
upon the chest and inserted into the esophagus for subsequent induction of ventricular 101 
fibrillation. Rectal, esophageal and tympanic temperatures were continuously monitored 102 
using thermal probes (Harvard Apparatus, Paris, France). Throughout the protocol, external 103 
electrocardiogram was recorded, as well as arterial blood pressure from a catheter 104 
implanted into the ear artery. Data were digitalized and analyzed using the data acquisition 105 
software HEM v3.5 (Notocord, Croissy-sur-Seine, France).  106 
Cardiac arrest and cardiopulmonary resuscitation 107 
After animal preparation and subsequent stabilisation, ventricular fibrillation was 108 
induced by passing an alternative current (10 V, 4 mA; 2 min) between the implanted 109 
electrodes. Mechanical ventilation was stopped at the onset of fibrillation and throughout 110 
the subsequent period of cardiac arrest. After either 5 or 10 min of untreated fibrillation, 111 
cardiopulmonary resuscitation was started using cardiac massage (~ 200 beats/min), 112 
electric attempts of defibrillation (5-10 J/kg) and intravenous administration of epinephrine 113 
(15 µg/kg i.v.). Resumption of spontaneous circulation (ROSC) was considered as an 114 
organized cardiac rhythm associated with a mean arterial pressure above 40 mmHg during 115 
at least 1 min. After ROSC, administration of epinephrine was further permitted during a 116 
maximum of 7 h at a dosage appropriately adjusted to maintain mean arterial pressure at 117 
~80 mmHg. Mechanical ventilation was continued until weaning and awakening of the 118 
animals. Rabbits subsequently returned to their cage for a survival follow-up. They received 119 
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antibiotics (enrofloxacine, 5 mg/kg i.m.) during 7 days and analgesics (buprenorphine, 30 120 
µg/kg s.c.) during 3 days. 121 
Experimental protocol 122 
As shown in Figure 1, rabbits randomly underwent either 5 or 10 min of cardiac arrest 123 
with subsequent cardiopulmonary resuscitation. For each duration of cardiac arrest, rabbits 124 
were randomly allocated to resuscitation under normothermic conditions (Control5’ and 125 
Control10’ groups, respectively) or with hypothermia induced by TLV (H-TLV5’ and H-TLV10’ 126 
groups, respectively). In these last two groups, TLV was started at the 10th min following 127 
cardiopulmonary resuscitation (i.e., after ROSC) by filling the lung with 10 ml/kg of 128 
perfluorocarbon (Fluorinert, 3M, Cergy, France) and then connecting the endotracheal tube 129 
to our prototype of  liquid ventilator (Supplemental Figure 1).11, 17, 18 This ventilator was set 130 
to a tidal volume of ~7-10 ml/kg of body weight with a respiratory rate of 6 breaths/min. For 131 
each breath, the ventilator pumped into and out of the lungs the tidal volume of liquids. The 132 
perfluorocarbon mixture was bubbled with 100% O2. The temperature of the heat 133 
exchanger was adjusted to maintain esophageal and tympanic temperatures at a target 134 
temperature of ~32°C. After 20 min of TLV and achie vement of the hypothermic target 135 
temperature, the perfluorocarbon was evacuated from the lungs by gravity and the 136 
endotracheal tube was again connected to a conventional mechanical ventilator. 137 
Hypothermia was further maintained at 32°C during 3  h, if necessary using cold blankets. 138 
Animals were subsequently rewarmed using infra-red lights and thermal pads until weaning 139 
from conventional ventilation and awakening. Animals were housed in a closed cage 140 
enriched in O2 during 2-3 days to avoid hypoxic episodes. In order to determine whether 141 
hypothermic TLV properly protects through very fast cooling, we investigated two randomly 142 
allocated additional groups submitted to 10 min of cardiac arrest. The first of these groups 143 
(Saline 10’) was submitted to 3 h of conventional hypothermia through the combination of 144 
cold saline administration (30 ml/kg i.v., NaCl 0.9% at 4°C) and external cooling. The 145 
second additional group was submitted to an episode of TLV with normothermic 146 
perfluorocarbons (N-TLV10’ group) to determine their proper effects.  147 
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 In order to further investigate the effects of hypothermic TLV, additional rabbits were 148 
included in the Control10’ and H-TLV10’ groups, respectively. These animals were 149 
euthanized one hour after the cardiac arrest episode for collection of myocardial and blood 150 
samples for caspase activity assays and measurement of circulating troponin I, 151 
respectively. 152 
Neurological and cardiac dysfunction assessment 153 
Neurological dysfunction was evaluated daily in surviving animals using a clinical 154 
score  previously validated in rabbits,23 as shown in Supplemental Table 1 (0-10% = 155 
normal; 100% = brain death). After 7 days of follow-up, surviving rabbits were 156 
reanesthetized and a pressure catheter (SciSense, London, Ontario, Canada) was 157 
introduced into the left ventricle through the right carotid artery for measurement of end-158 
diastolic pressures as well as positive and negative left ventricular rate of pressure 159 
development (dP/dtmax and dP/dtmin). These parameters were also measured in a group of 160 
Sham rabbits that were neither submitted to cardiac arrest nor hypothermia. 161 
Blood chemistry and caspase activity assay 162 
Blood pH, carbon dioxide and oxygen partial pressures (pCO2 and pO2, respectively) 163 
were assessed from arterial blood samples with an ABL 77 series analyser (Radio-meter 164 
SA, France). Blood lactate was determined on an Accutrend® Plus analyser (Roche 165 
Diagnostics, Mannheim, Germany). Liver and renal functions were evaluated by measuring 166 
the alanine aminotransferase (ALAT) and creatinine concentrations (Prestige 24i, Tokyo-167 
Boehi, Japan). Troponin I and Creatinine Kinase were measured by an off-site laboratory 168 
(IDEXX Laboratories, Alfortville, France).  169 
Caspase 3 activity was assayed from cardiac samples, as previously described.24 170 
Briefly, tissues were homogenized in cold buffer (25 mM HEPES pH 7.5, 5 mM MgCl2, 171 
2 mM EDTA, 0.1% Triton X-100, 2 mM dithiothreitol, 1 mM PMSF, 5 µl/ml protease cocktail 172 
inhibitor P8340; Sigma-Aldrich, St Louis, MO, USA). Homogenates were centrifuged and 173 
supernatants collected. Proteins (90 µg) were incubated in caspase assay buffer (50 mM 174 
HEPES pH 7.4, 100 mM NaCl, 1 mM EDTA, 10 mM dithiothreitol, Triton X-100 0.1%, 175 
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glycerol 10%). Enzymatic reaction was started by addition of 0.2 mM of the fluorogenic 176 
substrates ac-DEVD-AFC (Biomol Research Laboratories, Hambourg, Germany). 177 
Fluorescent arbitrary units were converted into pmol/mg protein/h using a standard curve of 178 
free AFC (Biomol Research Laboratories, Hambourg, Germany). 179 
Histological analyses 180 
After 7 days of follow-up after cardiac arrest, the surviving rabbits were finally 181 
euthanized for pathological analyses of the heart, lung, kidney, liver and brain. These 182 
organs were also removed and analyzed in the animals died before the end of the follow-183 
up. For lungs, a slice was sampled from each lobe (5 per lung). For the heart, we analyzed 184 
a mid heart transversal biventricular section. For kidneys, two slices were studied for each 185 
organ. We used a 0-3 score system to blindly quantify the severity of each organ alteration, 186 
as shown in Supplemental Tables 2 and 3 (0=normal; 3=very severe lesion). The overall 187 
brain score was the mean value obtained for cortex, hippocampus and cerebellum, as 188 
previously described.23 For lungs, we assessed two separate scores for cardiogenic lesions 189 
(serous edema and/or congestion) and infectious complication of bronchopneumonia, 190 
respectively. The first panels of Figures 2 and 3 illustrate typical normal and pathological 191 
aspects of the different organs. 192 
Statistical analyses 193 
Data were expressed as mean±SEM. Hemodynamic and biochemical parameters 194 
were compared between the different groups and corresponding controls using a two-way 195 
ANOVA for repeated measures. Post-hoc analyses were performed at each time-point as 196 
compared to controls using a Student t-test with Bonferroni correction. Values were not 197 
compared between the different time-points in order to avoid multiple comparisons. In each 198 
experimental group, neurological dysfunction and histological scores were compared to the 199 
corresponding control group using a Mann-Whitney non parametric test. Survival curves 200 
were obtained using a Kaplan-Meier analysis and were compared to the corresponding 201 
control group using a log-rank test. These last analyses took only into account the animals 202 
that achieved ROSC. Significant differences were determined at P≤0.05. 203 
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Results  204 
Seventy rabbits were included in the present study and submitted to cardiac arrest 205 
(n=10, 10, 15, 15, 10 and 10 in the Control5’, H-TLV5’, Control10’, H-TLV10’, Saline10’ and N-206 
TLV10’ groups, respectively). 207 
As shown in Table 1, all rabbits subjected to 5 min of cardiac arrest were successfully 208 
resuscitated (Control5’ and H-TLV5’ groups) whereas only 10/15  were successfully 209 
resuscitated in the Control10’ and H-TLV10’ groups, respectively. This rate was 7/10 in 210 
Saline10’ and N-TLV10’ groups. Regardless the duration of the cardiac arrest, the time to 211 
resumption of spontaneous circulation was not significantly different among groups for each 212 
duration of cardiac arrest.  213 
As illustrated in Figure 4, esophageal, tympanic and rectal temperatures were not 214 
significantly different among groups at baseline. A mild and passive decrease in body 215 
temperature was observed in the Control5’ and Control10’ groups after cardiac arrest but this 216 
remained within the normothermic range. In H-TLV groups, esophageal and tympanic 217 
temperatures decreased very rapidly after the institution of TLV. As example, tympanic 218 
temperature achieved 33.3±0.5 and 32.5±0.3 °C in H- TLV5’ and H-TLV10’ within 10 min after 219 
the onset of the cooling protocol, respectively. In the Saline 10’ group, such tympanic 220 
temperatures were achieved after ~30 min. Regarding esophageal and rectal temperatures, 221 
the time to achieve 32 to 33°C was less than 5 and 20 min in H-TLV10’ whereas this was 222 
more than 45 and 60 min in Saline10’, respectively. In the N-TLV10’ group, body 223 
temperatures did not significantly differ from the Control10’ values throughout the 224 
experimental protocol. 225 
As shown in Table 2, heart rate significantly decreased during the hypothermic phase 226 
in hypothermic groups as compared to corresponding controls (e.g., -21%, -28% and -31% 227 
at 60 min after cardiac arrest in H-TLV5’, H-TLV10’ and Saline10’  vs corresponding controls, 228 
respectively). Mean arterial pressure was not significantly different between groups 229 
throughout the experimental protocol since epinephrine administration was permitted to 230 
maintain a ~80 mmHg value during 7 h after cardiac arrest. As shown in Table 1, the total 231 
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amount of epinephrine administered throughout cardiopulmonary resuscitation was 232 
however significantly lower in H-TLV10’ vs Control10’ (128±128 vs 684±118 µg/kg, 233 
respectively), suggesting a favorable hemodynamic effect of hypothermic TLV. We did not 234 
observe such a significant difference in H-TLV5’ vs Control5’ but epinephrine dosages were 235 
much lower (174±81 vs 207±58 µg/kg, respectively). In Saline10’ and N-TLV10’ groups, 236 
epinephrine dosages were also not different from Control10’. After discontinuation of any 237 
pharmacological support (e.g., at 8 h after cardiac arrest), the lactate levels were 238 
significantly lower in H-TLV5’ vs Control5’ (1.2±0.2 vs 4.8±1.7 mmol/l) and in H-TLV10’ vs 239 
Control10’ (3.6±0.7 vs 7.0±1.7 mmol/l). Those levels were not significantly different among 240 
Saline10’ and N-TLV10’ groups as compared to Control10’ (5.9±0.7 and 7.6±0.6 vs 7.0±1.7 241 
mmol/l). 242 
 As shown in Figure 5, we observed a severe acidosis with an increase in pCO2 and a 243 
decrease in pO2 in all groups following cardiac arrest. In H-TLV5’, pO2 was lower 15 min 244 
after cardiac arrest as compared to Control5’. This could be expected as control animals 245 
were ventilated with oxygen whereas TLV rabbits underwent liquid ventilation by that time
’
’’
. 246 
At 180 min, gas exchanges were conversely improved in H-TLV groups as compared to 247 
controls. As example, blood pH and pO2 increased whereas pCO2 decreased in H-TLV10’ vs 248 
Control10’, respectively. Importantly, all the animals were submitted to conventional 249 
ventilation at that time point, with standardized ventilation parameters. As illustrated in 250 
Figure 2, the safety of TLV for lungs was also documented by histology demonstrating 251 
cardiogenic lesions (serous edema and/or congestion) or infectious complications of 252 
bronchopneumonia to a similar extent in TLV groups vs corresponding controls. 253 
 As shown in Table 2, renal function was not affected after cardiac arrest in all groups 254 
since plasma creatinine levels remained within usual values. Conversely, we observed an 255 
increase in the liver enzyme ALAT with no difference among TLV and corresponding 256 
controls. Kidney and liver lesions were mild with no difference among groups (Figure 2, 257 
panel B).  258 
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 As illustrated in Figure 6, neurological dysfunction was significantly attenuated in H-259 
TLV groups as compared to controls. This difference was significant as early as the 2nd day 260 
following cardiac arrest in H-TLV5’ vs Control5’ (panel A) whereas this was observed within 261 
24h of follow-up in H-TLV10’ vs Control10’ (panel B). In Saline10’, a transient improvement in 262 
neurological recovery was observed at day 1 but this was no longer significant at day 2 263 
after cardiac arrest. As illustrated in Figure 3 (panel B), the neuroprotective effect of 264 
hypothermic TLV was further demonstrated by a significant decrease in the severity of the 265 
ischemic disorders in the brain in H-TLV5’ and H-TLV10’ as compared to Control5’ and 266 
Control10’ groups, respectively. No any protection was conversely seen in Saline10’ and N-267 
TLV10’ as compared to Control10’. 268 
 A significant difference in survivals was also evidenced between H-TLV groups and 269 
corresponding controls, as illustrated in Figure 6 (panels C and D). At the end of the follow-270 
up, 9/10 and 7/10 rabbits survived in the H-TLV5’ and H-TLV10’ groups as compared to 5/10 271 
and 0/10 in Control5’ and Control10’, respectively. Conversely, survival was not significantly 272 
improved in Saline10’ and N-TLV10’ as compared to Control10’.  273 
   As illustrated in Figure 3 (panel B), myocardial foci of necrosis were less frequent in 274 
H-TLV10’ vs Control10’, demonstrating a cardioprotective effect of hypothermic TLV. No 275 
difference was conversely seen between Saline10’ and N-TLV10’ as compared to Control10’. 276 
In surviving animals, the functional myocardial sequels of cardiac arrest were also 277 
evaluated after 7 days of follow-up. As shown in Supplemental Table 4, mean blood 278 
pressure and heart rate in the conscious state were not different among groups as 279 
compared to a Sham group. After anesthesia, end diastolic left ventricular pressure, 280 
dP/dtmax and dP/dtmin min were also not different between groups, suggesting that there was 281 
no major functional myocardial alterations in those surviving animals. 282 
 To further explore the cardioprotective effect of hypothermic TLV, eight additional 283 
rabbits were included in the Control10’ and H-TLV10’ groups for a surrogate study dedicated 284 
to the caspase activity assays and measurement of troponin I levels. As shown in 285 
supplemental Figure 2, troponin I measured 60 min after cardiac arrest significantly 286 
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decreased in H-TLV10’ as compared to Control10’ (1.3±0.3 vs 70.7±30.4 ng/ml, respectively). 287 
The cardioprotective effect of hypothermic TLV was also supported by a decrease in 288 
caspase 3 activity as compared to control (6.2±1.2 vs 10.0±1.2 pmol/mg prot/h, 289 
respectively). 290 
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Discussion 291 
 The present study provides the proof of concept that ultra-fast whole body cooling 292 
with hypothermic TLV limits the post-cardiac arrest syndrome when instituted after ROSC in 293 
a rabbit model of ventricular fibrillation. Interestingly, we observed potent neuro- and 294 
cardioprotections with hypothermic TLV which remains a safe procedure for the lungs. As 295 
we used only 3 h of hypothermia, this also suggested that very early hypothermia after 296 
ROSC does not need to be prolonged to produce a strong clinical benefit. Importantly, this 297 
benefit was directly related to cooling rapidity with TLV since a conventional cooling with 298 
cold saline and external blankets was not significantly protective in similar conditions.  299 
Proper effects of the perfluorocarbon are unlikely as related to the lack of protection with 300 
normothermic TLV.  301 
Our first finding is the rapidity of TLV-induced cooling since esophagal and brain 302 
temperatures achieved ~32-33°C within only 10 min. In comparison, a conventional 303 
hypothermic protocol (cold saline infusion + external cooling) requires ~30 and 45 min to 304 
similarly reduce these temperatures. The rapid cooling elicited by TLV was directly related 305 
to the tidal exchange of the liquid since simple repetitive pulmonary lavages with a 4°C 306 
perfluorocarbon requires more than 60 min to decrease the tympanic temperature to 32°C 307 
in the same species.20 In large animals, hypothermic TLV was also reported to afford a very 308 
fast cooling and to reduce the pulmonary artery temperature to 32°C within 9-10 min when 309 
instituted intra-arrest in a ventricular fibrillation model in swine.22  310 
 Importantly, the rapid hypothermia elicited by TLV was associated with a potent 311 
neurological protection and an increase in survival rate as compared to control conditions. 312 
In animal studies, it is admitted that the neuroprotective effect of hypothermia is time 313 
dependent and that a large part of the protection is lost when cooling is delayed.25 For 314 
example, in a canine model of cardiac arrest, the neurological protection was lost after only 315 
15 min of delay before the onset of hypothermia after ROSC. 25 In the present study, we 316 
observed a very potent benefit of hypothermia when achieved rapidly after ROSC with TLV 317 
whereas a conventional hypothermia was not significantly protective. Recent experiments 318 
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have also shown that hypothermia started before ROSC (e.g., intra-arrest hypothermia) can 319 
afford an additional benefit7, 8 but this might be difficult to translate this concept into human 320 
clinical practice. All these findings demonstrate that most of the possible benefits of 321 
hypothermia can be lost within minutes after ROSC, further supporting the need of devices 322 
eliciting ultra-fast cooling such as TLV in the present study. 323 
 Importantly, the benefit of hypothermic TLV observed in our conditions was 324 
produced by a short hypothermic episode (3 h), whereas the current recommendations in 325 
humans are maintenance of hypothermia during 24-36 h.1, 2 We choose this short duration 326 
since previous experiments have shown that when achieved very early, the duration of the  327 
hypothermia does not need to be prolonged to afford an effective neuroprotection, e.g., in a 328 
gerbil model of global ischemia. 26 Mice studies also noted that 1 h of cooling after ROSC 329 
was sufficient to generate a significant clinical benefit. 7, 8 When the severity of the ischemic 330 
insult increases or when the onset of cooling is delayed, it is conversely well established 331 
that prolonging hypothermia is critical for achieving a maximal neurological protection.27, 28 332 
As example, a prolonged cooling allowed to provide enduring behavioral and histological 333 
protection in rats submitted to permanent middle cerebral artery occlusion, even when 334 
delayed after onset of ischemia.27  335 
 Another important beneficial effect of hypothermic TLV is the cardioprotection 336 
observed here like that previously shown in animal models of coronary artery occlusion.11, 337 
17, 18
 This was especially observed after 10 min of cardiac arrest since myocardial lesions 338 
were minor in the groups submitted to only 5 min of cardiac arrest. This was evidenced by a 339 
limitation in myocardial necrosis and a preservation of myocardial functional performance in 340 
surviving rabbits. Cardioprotection was also observed very early after cardiac arrest since 341 
troponin I release and caspase 3 activity were significantly decreased within 60 min after 342 
resuscitation in H-TLV10’ vs Control10’. In animal models of focal myocardial ischemia, the 343 
window of protection with hypothermia is virtually limited to the ischemic phase, whereas 344 
cooling at reperfusion is ineffective at reducing infarct-size in most experimental studies.12 345 
In the present study, hypothermia was instituted after global reperfusion (ROSC) but it is 346 
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reasonable to speculate that the myocardium remains momentarily and partially ischemic 347 
even after ROSC. This can explain that a very rapid cooling with TLV can still afford a 348 
beneficial effect even if instituted after ROSC and systemic reperfusion. Improved post-349 
resuscitation myocardial function have interestingly also be observed with intra-arrest rapid 350 
head cooling.29 Generalized hypothermia could even potentially afford a protection of the 351 
liver and/or the kidney.30 As these organs were mildly altered in control conditions in the 352 
present study, we were not able to show any difference with hypothermic TLV.  353 
 Importantly, TLV was a safe procedure for the lungs. Even, we observed improved 354 
gas exchanges using standardized ventilatory parameters in TLV vs control groups at 3 h 355 
after cardiac arrest. After weaning from ventilation, animals were however maintained in a 356 
cage enriched in oxygen to avoid hypoxic episodes.11 In pigs, intra-arrest liquid ventilation 357 
was indeed demonstrated to alter lung function since activation of pulmonary macrophages 358 
might alter gas exchanges after resumption to conventional ventilation.21, 22 In our study, the 359 
tolerance of TLV was shown by histological examinations and this is supported by several 360 
reports from the literature demonstrating that liquid ventilation can even protect the lungs.19, 361 
20
 Several prototypes of liquid ventilator have been developed and the clinical translation of 362 
this concept might accordingly be feasible when those devices will be available for a clinical 363 
use. 31  To date, the current prototypes are mostly developed for a paediatric use31  and the 364 
translation of TLV-induced hypothermia would be accordingly first possible in newborns 365 
presenting global ischemia. Further developments might also ultimately permit a translation 366 
in adult patients. 367 
 Our study has several limitations. First, neurological dysfunctions were assessed on 368 
the basis of clinical and histological parameters. Other more functional tests or imaging 369 
would also be important. Second, histological analyses were performed in all animals, 370 
irrespectively of their survival time. This would have lead to an underestimation of the 371 
histological scores in some animals who died very early after the cardiac arrest. However, 372 
since the lower scores were observed in the group that lived for the longer time (H-TLV10’), 373 
the latter limitation should not actually impact our conclusions.  374 
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In conclusion, ultra-fast cooling instituted by hypothermic TLV limits the post-cardiac 375 
arrest dysfunction with associated neuro- and cardioprotective effects. Importantly, TLV 376 
was a safe procedure for the lungs in our experimental conditions. The beneficial effects of 377 
hypothermic TLV were probably directly related to the rapidity in temperature decrease 378 
since myocardial cell death inhibition was evidenced even very early following resuscitation. 379 
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Legends of Figures 496 
 497 
Figure 1: Experimental protocol 498 
CA, cardiac arrest; TLV, total liquid ventilation initiated; H-TLV, hypothermic TLV; N-TLV, 499 
normothermic TLV; Saline, hypothermia induced by intravenous administration of cold 500 
saline combined to external cooling; ROSC, resumption of spontaneous circulation.  501 
 502 
Figure 2:  503 
Panel A: Examples of normal or pathological histological appearances of the kidney, liver 504 
and lungs in the TLV and control groups, respectively. In kidney, lesions consisted in dilated 505 
regenerative proximal tubules (arrows, bar=120 µm). In liver, we observed systematized 506 
clarification of hepatocytes (arrows, bar=120 µm). In lungs, lesions were congestion and 507 
serous edema (arrows in the left lung panel, bar=120 µm) or foci of bronchopneumonia 508 
(arrows in the right lung panel, bar=120 µm).  509 
Panel B: Histological scores of alteration in kidney, liver and lungs of rabbits from the 510 
different groups. For lungs, we assessed two separate scores for cardiogenic lesions and 511 
infection complications, respectively. Open circles represents individual scores and the 512 
thick line represents the median value of corresponding group. 513 
 * p<0.05 vs corresponding control; TLV, total liquid ventilation; H-TLV, hypothermic TLV; 514 
N-TLV, normothermic TLV; Saline, hypothermia induced by intravenous administration of 515 
cold saline combined to external cooling. 516 
 517 
Figure 3:  518 
Panel A: Examples of normal or pathological histological appearances of the brain and the 519 
heart in the TLV and control groups, respectively. In brain, ischemic disorders consisted in 520 
ischemic pyramidal cells with pycnotic nucleus in the hippocampus (arrows, bar=30 µm), in 521 
laminar necrosis of Purkinje cells in the cerebellum (arrows, bar=30 µm) or in numerous 522 
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ischemic neurons in the cortex (arrows, bar=30 µm), respectively. In the myocardium, we 523 
observed foci of cardiomyocytes necrosis (arrows, bar=120 µm).  524 
Panel B: Histological scores of alteration in the brain and heart of rabbits from the different 525 
groups. Open circles represents individual scores and the thick line represents the median 526 
value of the corresponding group. 527 
 * p<0.05 vs corresponding control; TLV, total liquid ventilation; H-TLV, hypothermic TLV; 528 
N-TLV, normothermic TLV; Saline, hypothermia induced by intravenous administration of 529 
cold saline combined to external cooling. 530 
 531 
Figure 4: Esophageal, tympanic and rectal temperatures in the different experimental 532 
groups.  533 
* p<0.05 vs corresponding control; n=10 in each experimental group; TLV, total liquid 534 
ventilation; H-TLV, hypothermic TLV; N-TLV, normothermic TLV; Saline, hypothermia 535 
induced by intravenous administration of cold saline combined to external cooling. 536 
 537 
Figure 5: Blood pH, pCO2 and pO2 in the different experimental groups. 538 
* p<0.05 vs corresponding control; n=10 in each experimental group; TLV, total liquid 539 
ventilation; H-TLV, hypothermic TLV; N-TLV, normothermic TLV; Saline, hypothermia 540 
induced by intravenous administration of cold saline combined to external cooling. 541 
 542 
Figure 6:  543 
Panels A and B: Neurological dysfunction scores at days 1, 2 and 7 following resuscitation 544 
in the different experimental groups submitted to 5 min or 10 min of cardiac arrest, 545 
respectively. Open circles represent individual scores and the thick line represents the 546 
median value of the corresponding group. Only animals achieving resumption of 547 
spontaneous circulation were included. 548 
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Panels C and D: Kaplan-Meyer survival curves in the different experimental groups 549 
submitted to 5 min or 10 min of cardiac arrest, respectively. Only animals achieving 550 
resumption of spontaneous circulation were included. 551 
* p<0.05 vs corresponding control; TLV, total liquid ventilation; H-TLV, hypothermic TLV; N-552 
TLV, normothermic TLV; Saline, hypothermia induced by intravenous administration of cold 553 
saline combined to external cooling. 554 
 555 
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Figure 3 558 
 30 
Figure 4 559 
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Figure 6 561 
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Table 1 : Groups characteristics during cardiopulmonary resuscitation, including the rate of 562 
successful resuscitation, the time to resumption of spontaneous circulation (ROSC) and the  563 
total amount of epinephrine administered throughout the protocol. 564 
* p<0.05 vs corresponding control value; TLV, total liquid ventilation; H-TLV, hypothermic 565 
TLV; N-TLV, normothermic TLV; Saline, hypothermia induced by intravenous administration 566 
of cold saline combined to external cooling. 567 
   
n 
  
 Rate of successfull 
resuscitation  
  
ROSC  (min) 
  
Epinephrine dose 
(µg/kg) 
  
          
  Control 5'  10  10/10  2.4±0.3  207±58  
  H-TLV 5'  10  10/10  2.3±0.3  174±81  
  Control 10'  15  10/15  4.8±0.4  684±118  
  H-TLV 10'   15   10/15   4.2±0.8   128±128 *  
  Saline 10'  10  7/10  3.7±0.7  430±126  
  N-TLV 10'  10  7/10  3.7±0.4  509±64  
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Table 2 : Mean arterial pressure, heart rate, plasma creatinine and alanine aminotransferase 568 
concentrations (ALAT)  throughout the experimental protocol in the different groups. 569 
  Cardiopulmonary resuscitation 
  
n Baseline 
15min 60min  180min 360min 480min 
Day 1 (n) 
Epinephrine perfusion No Yes Yes Yes Yes No  
Heart rate (beat/min) 
  Control 5' 10 257±11 222±8 221±7 243±11 216±7 220±9 234±8 (10) 
  H-TLV 5' 10 259±10 202±12 174±6 * 177±9 * 245±9 234±8 244±10 (10)  
  Control 10' 10 263±10 219±6 220±10 198±8 221±11 231±13 256±17 (7) 
  H-TLV 10' 10 267±8 167±10 * 158±8 * 167±11 208±12 240±11 252±7 (8) 
  Saline 10' 7 266±7 200±10 153±7 * 155±13 * 219±10 218±10 226±16 (6) 
  N-TLV 10' 7 256±13 216±19 207±9 213±12 207±9 221±15 240±28 (2) 
Mean arterial pressure (mmHg) 
  Control 5' 10 81±3 83±4 82±3 83±1 83±4 80±4 83±4 (10) 
  H-TLV 5' 10 80±7 81±3 82±5 82±3 83±3 79±3 82±4 (10) 
  Control 10' 10 80±5 82±3 83±3 81±4 83±2 80±3 79±4 (7) 
  H-TLV 10' 10 83±4 81±4 82±3 81±3 81±4 80±4 79±6 (8) 
  Saline 10' 7 80±8 86±6 89±2 78±5 82±5 76±6 83±9 (6) 
  N-TLV 10' 7 78±7 78±5 78±1 78±4 78±5 75±7 88±4 (2)  
Plasma creatinine concentrations (mg/l) 
  Control 5' 10 10±1 11±1 - 10±1 - - 10±1 (10) 
  H-TLV 5' 10 10±0 12±1 - 11±1 - - 10±1 (10) 
  Control 10' 10 9±1 13±1 - 14±2 - - 11±1 (7) 
  H-TLV 10' 10 10±0 13±1 - 12±1 - - 11±1 (8) 
  Saline 10' 7 9±1 10±1 - 10±1 - - 10±1 (6) 
  N-TLV 10' 7 9±1 11±1 - 12±1 - - 13±6 (2) 
Plasma ALAT concentrations (UI/l) 
  Control 5' 10 29±5 31±4 - 33±4 - - 35±9 (10) 
  H-TLV 5' 10 25±3 26±2 - 43±5  - - 30±6 (10) 
  Control 10' 10 44±13 79±25 - 115±32 - - 60±17 (7) 
  H-TLV 10' 10 48±3 65±5 - 111±27 - - 83±14 (8) 
  Saline 10' 7 32±2 48±4 - 101±30 - - 62±27 (6) 
  N-TLV 10' 7 31±5 66±10 - 96±13 - - 94±37 (2) 
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* p<0.05 vs corresponding control value; TLV, total liquid ventilation; H-TLV, hypothermic 570 
TLV; N-TLV, normothermic TLV; Saline, hypothermia induced by intravenous administration 571 
of cold saline combined to external cooling. 572 
